Cyclosporin a treatment induces overexpression of P-glycoprotein in the kidney and other tissues

American Journal of Physiology

Volumn 270, Issue 5 PART 2, 1996, Pages

  Jette, Lucie ^a,b   Beaulieu, Edith ^a,b   Leclerc, Jean Marie ^a   Béliveau, Richard ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; VALSPODAR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG TRANSPORT; KIDNEY TUBULE EPITHELIUM; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; AFFINITY LABELS; ANIMALS; AZIDES; CYCLOSPORINE; CYCLOSPORINS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; KIDNEY; MALE; MICROVILLI; P-GLYCOPROTEIN; PRAZOSIN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0029938602     PISSN: 00029513     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajprenal.1996.270.5.f756     Document Type: Article

References (34)

1. Booth, A. G., and A. J. Kenny. A rapid method for the preparation of microvilli from rabbit kidney. Biochem. J. 142: 575-581,1974.
2. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
3. Charuk, J. H. M., T. W. Loo, D. M. Clarke, and R. A. F. Reithmeier. Interaction of rat kidney P-glycoprotein with a urinary component and various drugs including cyclosporin A. Am. J. Physiol. 266 (Renal Fluid Electrolyte Physiol. 35): F66-F75, 1994.
4. Chaudhary, P. M., and I. B. Roninson. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. CancerInst. 85: 632-639, 1993.
5. Cordon-Cardo, C., J. P. O'Brien, L. Boccia, D. Casals, J. R. Bertino, and M. R. Melamed. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38: 1277-1287, 1990.
6. Demeule, M., and R. Béliveau. Cyclosporin inhibits phosphate transport and stimulates alkaline phosphatase activity in renal BBMV. Am. J. Physiol. 260 (Renal Fluid Electrolyte Physiol. 29): F518-F524, 1991.
7. Demeule, M., S. Giroux, G. Murphy, and R. Béliveau. Cyclosporin treatment alters protein phosphorylation in kidney membranes. Biochem. Cell Biol. 72: 143-151, 1994.
8. Faulds, D., K. L. Goa, and P. Benfield. Cyclosporin. A review of its pharmacodynamic and phamacokinetic properties, therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040, 1993.
9. Fojo, A. T., K. Ueda, D. J. Slamon, D. G. Poplack, M. M. Gottesman, and I. Pastan. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Nail. Acad. Sei. USA 84: 265-269, 1987.
10. Ford, J. M., and W. N. Hait. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42: 155-1991, 1990.
11. Foxwell, B. M., A. Mackie, V. Ling, and B. Ryffel. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol. Pharmacol. 36: 543-546, 1989.
12. Georges, E., G. Bradley, J. Gariepy, and V. Ling. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc. NatlAcad. Sei. USA 87: 152-156, 1990.
13. Gottesman, M. M., and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Anna. Rev. Biochem. 62: 385-427, 1993.
14. Greenberger, L. M., C.-P. H. Yang, E. Gindin, and S. B. Horwitz. Photoaffinity probes for the ai-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J. Biol. Chem. 265: 4394-4401, 1990.
15. Haynes, M., L. Fuller, D. H. Haynes, and J. Miller. Cyclosporin partitions into phospholipids vesicles and disrupts membrane architecture. Immunol. Lett. 11: 343-349, 1985.
16. Herzog, C. E., M. Tsokos, S. E. Bates, and A. T. Fojo. Increased mrfr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J. Biol. Chem. 268: 2946-2952, 1993.
17. Hill, B. T., R. D. H. Whelan, H. C. Hurst, and S. McClean. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. Cancer 73: 2990-2999, 1994.
18. Jette, L., B. Têtu, and R. Béliveau. High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta 1150: 147-154, 1993.
19. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature Land. 227: 680-685, 1970.
20. Larssson, R., H. Fridborg, K. Csoka, J. Bergh, and P. Nygren. Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity. AnticancerRes. 12:1581-1586, 1992.
21. Lieberman, D. M., R. A. F. Reithmeier, V. Ling, J. H. M. Charuk, H. Goldberg, and K. L. Skorecki. Identification of P-glycoprotein in renal brush border membranes. Biochem. Biophys. Res. Commun. 162: 244-252, 1989.
22. Lum, B. L., M. P. Gosland, S. Kaubisch, and B. I. Sikic. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13: 88-109, 1993.
23. Mason, J. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev. 42: 423-434, 1989.
24. 2+ ionophores. Biochim. Biophys. Acta 886: 353-360, 1986.
25. Orlowski, M., and A. Meister, γ-Glutamyl-paranitroanilide: a new convenient substrate for determination and study of L- and D-γ-glutamyltranspeptidase activities. Biochim. Biophys. Acta 73: 679-681, 1963.
26. Raderer, M., and W. Scheithauer. Clinical trials of agents that reverse multidrug resistance. Cancer 72: 3553-3563, 1993.
27. Saeki, T., K. Ueda, Y. Tanigawara, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK 506. J. Biol. Chem. 268: 6077-6080, 1993.
28. Sakata, A., I. Tamai, K. Kawazu, Y. Deguchi, T. Ohnishi, A. Saheki, and A. Tsuji. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48: 1989-1992, 1994.
29. Schinkel, A. H., J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagwnaar, L. van Deemter, C. A. A. M. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. J. te Riele, A. J. M. Berns, and P. Borst. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the bloodbrain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
30. Szamel, M., P. Berger, and K. Resch. Inhibition of T lymphocyte activation by cyclosporin A: interference with the early activation of plasma membrane phospholipid metabolism. J. Immunol. 136: 264-269, 1986.
31. Thiebaut, F., T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein p!70: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37: 159-164, 1989.
32. Twentyman, P. R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43: 109-117, 1992.
33. Vayuvegula, B., L. Slater, J. Meador, and S. Gupta. Correction of altered plasma membrane potential. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia. Cancer Chemother. Pharmacol. 22: 163-168, 1988.
34. Wagner, O., E. Schreier, F. Heitz, and G. Maurer. Tissue distribution, disposition, and metabolism of cyclosporine in rats. DrugMetabol. Dispos. 15: 377-383, 1987.